Accessibility Menu
EyePoint Pharmaceuticals Stock Quote

EyePoint Pharmaceuticals (NASDAQ: EYPT)

$11.47
(-2.9%)
-0.34
Price as of October 22, 2025, 3:58 p.m. ET

KEY DATA POINTS

Current Price
$11.47
Daily Change
(-2.9%) $0.34
Day's Range
$11.33 - $12.03
Previous Close
$11.47
Open
$11.71
Beta
1.22
Volume
-
Average Volume
980,581
Market Cap
789.2M
Market Cap / Employee
$11.45M
52wk Range
$3.91 - $14.91
Revenue
-
Gross Margin
0.94%
Dividend Yield
N/A
EPS
-$2.68
CAPs Rating
-
Industry
Pharmaceuticals

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

EyePoint Pharmaceuticals Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
EYPT+6.51%+149.73%+20.09%-64%
S&P+14.5%+93.32%+14.09%+402%

EyePoint Pharmaceuticals Company Info

EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$5.33M-43.7%
Gross Profit$4.63M-42.7%
Gross Margin86.82%1.6%
Market Cap$647.52M42.9%
Market Cap / Employee$3.92M0.0%
Employees16536.4%
Net Income-$59.43M-92.8%
EBITDA-$61.69M-80.5%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$71.14M-21.6%
Accounts Receivable$0.63M-54.5%
Inventory2.7-27.1%

Liabilities

Q2 2025YOY Change
Long Term Debt$21.82M-1.6%
Short Term Debt$0.00M-100.0%

Ratios

Q2 2025YOY Change
Return On Assets-56.09%-21.4%
Return On Invested Capital-48.71%12.1%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$63.81M-202.7%
Operating Free Cash Flow-$62.59M-210.2%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book1.961.821.102.1724.96%
Price to Sales9.5211.116.7512.6838.02%
Price to Tangible Book Value1.961.821.102.1724.96%
Enterprise Value to EBITDA-6.32-2.97-1.74-6.8714.11%
Return on Equity-74.7%-43.4%-53.5%-74.0%21.62%
Total Debt$23.21M$23.11M$24.08M$21.82M-6.35%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.